Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235166 | 0.87 | ACE (0.38) | ACENR1I3DRD2SIRT5SCN9A | |
| SCHEMBL2235104 | 0.87 | ACE (0.41) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2235338 | 0.85 | ACE (0.39) | ACENR1I3DRD2SIRT5 | |
| SCHEMBL2236787 | 0.82 | MEN1 (0.47) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2234466 | 0.82 | MEN1 (0.47) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2238532 | 0.82 | MEN1 (0.47) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2233656 | 0.80 | ACE (0.38) | ACENR1I3DRD2SIRT5SCN9A | |
| SCHEMBL2236732 | 0.80 | ACE (0.38) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2237504 | 0.80 | ACE (0.38) | ACENR1I3DRD2SIRT5TDP1 | |
| SCHEMBL2234465 | 0.80 | ACE (0.42) | ACENR1I3DRD2SIRT5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | ACE 473/4885NR1I3 1315/4885DRD2 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.